Assessing the metabolism of the olfactory circuit by use of
Humans
Alzheimer Disease
/ diagnostic imaging
Frontotemporal Dementia
/ diagnostic imaging
Fluorodeoxyglucose F18
Male
Female
Aged
Positron Emission Tomography Computed Tomography
/ methods
Middle Aged
Radiopharmaceuticals
Olfactory Pathways
/ diagnostic imaging
Brain
/ diagnostic imaging
Prospective Studies
Alzheimer’s disease
FDG PET
Frontotemporal dementia
Neurodegenerative disorders
Neuroimaging
Olfactory system
Journal
Alzheimer's research & therapy
ISSN: 1758-9193
Titre abrégé: Alzheimers Res Ther
Pays: England
ID NLM: 101511643
Informations de publication
Date de publication:
29 Oct 2024
29 Oct 2024
Historique:
received:
21
06
2024
accepted:
16
10
2024
medline:
30
10
2024
pubmed:
30
10
2024
entrez:
30
10
2024
Statut:
epublish
Résumé
The loss of olfactory function is known to occur in patients suffering from (behavioral variant) frontotemporal dementia ((bv)FTD) and Alzheimer's disease (AD), although different pathophysiological mechanisms underpin this clinical symptom in both disorders. This study assessed whether brain metabolism of the olfactory circuit as assessed by positron emission tomography (PET) imaging with 2-[fluorine-18]fluoro-2-deoxy-d-glucose ([ Patients presenting with cognitive decline were included from a prospectively kept database: (1) bvFTD patients, (2) AD patients and (3) patients with logopenic primary progressive aphasia (PPA). Metabolic rates were calculated for different regions of the olfactory circuit for each subgroup and compared with a cohort of subjects with normal brain metabolism. Additionally, in patients with a logopenic PPA pattern on PET-imaging, statistical parametric mapping (SPM) analysis was performed. The metabolism of subdivisions of the olfactory circuit as assessed by [ Metabolic dysfunction in the olfactory circuit is different in various neurodegenerative disorders. Further investigation of the correlations between the cerebral metabolism and the mechanisms which drive olfactory dysfunction is needed.
Identifiants
pubmed: 39472983
doi: 10.1186/s13195-024-01604-7
pii: 10.1186/s13195-024-01604-7
doi:
Substances chimiques
Fluorodeoxyglucose F18
0Z5B2CJX4D
Radiopharmaceuticals
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
241Informations de copyright
© 2024. The Author(s).
Références
Gallucci M, Limbucci N, Catalucci A, Caulo M. Neurodegenerative diseases. Radiol Clin North Am. 2008;46(4):799–817. vii.
pubmed: 18922294
doi: 10.1016/j.rcl.2008.06.002
Herholz K, Carter SF, Jones M. Positron emission tomography imaging in dementia. Br J Radiol. 2007;80(Spec 2):S160–7.
pubmed: 18445746
doi: 10.1259/bjr/97295129
Neary D, Snowden J, Mann D. Frontotemporal dementia. Lancet Neurol. 2005;4(11):771–80.
pubmed: 16239184
doi: 10.1016/S1474-4422(05)70223-4
Warren JD, Rohrer JD, Rossor MN. Clinical review. Frontotemporal dementia. BMJ. 2013;347:f4827.
pubmed: 23920254
pmcid: 3735339
doi: 10.1136/bmj.f4827
Spinelli EG, Tempini MLG, Shapiro KA. Chapter 32 - Speech and Language disorders. In: Lehner T, Miller BL, State MW, editors. Genomics, Circuits, and pathways in Clinical Neuropsychiatry. San Diego: Academic; 2016. pp. 503–31.
doi: 10.1016/B978-0-12-800105-9.00032-9
Doty RL. Olfactory dysfunction in neurodegenerative diseases: is there a common pathological substrate? Lancet Neurol. 2017;16(6):478–88.
pubmed: 28504111
doi: 10.1016/S1474-4422(17)30123-0
Jung HJ, Shin IS, Lee JE. Olfactory function in mild cognitive impairment and Alzheimer’s disease: a meta-analysis. Laryngoscope. 2019;129(2):362–9.
pubmed: 30565695
doi: 10.1002/lary.27399
Woodward MR, Amrutkar CV, Shah HC, Benedict RH, Rajakrishnan S, Doody RS, et al. Validation of olfactory deficit as a biomarker of Alzheimer disease. Neurol Clin Pract. 2017;7(1):5–14.
pubmed: 28243501
pmcid: 5310210
doi: 10.1212/CPJ.0000000000000293
Kamath V, Chaney GS, DeRight J, Onyike CU. A meta-analysis of neuropsychological, social cognitive, and olfactory functioning in the behavioral and language variants of frontotemporal dementia. Psychol Med. 2019;49(16):2669–80.
pubmed: 30520407
doi: 10.1017/S0033291718003604
Carnemolla SE, Hsieh JW, Sipione R, Landis BN, Kumfor F, Piguet O, et al. Olfactory dysfunction in frontotemporal dementia and psychiatric disorders: a systematic review. Neurosci Biobehav Rev. 2020;118:588–611.
pubmed: 32818582
doi: 10.1016/j.neubiorev.2020.08.002
Silva MME, Viveiros CP, Kotsifas NJE, Duarte A, Dib E, Mercer PBS, et al. Olfactory impairment in frontotemporal dementia: a systematic review and meta-analysis. Dement Neuropsychol. 2019;13(2):154–61.
pubmed: 31285789
pmcid: 6601313
doi: 10.1590/1980-57642018dn13-020003
Pardini M, Huey ED, Cavanagh AL, Grafman J. Olfactory function in corticobasal syndrome and frontotemporal dementia. Arch Neurol. 2009;66(1):92–6.
pubmed: 19139305
pmcid: 2987736
doi: 10.1001/archneurol.2008.521
Murphy C. Olfactory and other sensory impairments in Alzheimer disease. Nat Rev Neurol. 2019;15(1):11–24.
pubmed: 30532084
doi: 10.1038/s41582-018-0097-5
Jack CR Jr., Bennett DA, Blennow K, Carrillo MC, Dunn B, Haeberlein SB, et al. NIA-AA Research Framework: toward a biological definition of Alzheimer’s disease. Alzheimers Dement. 2018;14(4):535–62.
pubmed: 29653606
doi: 10.1016/j.jalz.2018.02.018
Chapleau M, Iaccarino L, Soleimani-Meigooni D, Rabinovici GD. The role of amyloid PET in Imaging Neurodegenerative disorders: a review. J Nucl Med. 2022;63(Suppl 1):s13–9.
doi: 10.2967/jnumed.121.263195
Matsunari I, Samuraki M, Chen WP, Yanase D, Takeda N, Ono K, et al. Comparison of 18F-FDG PET and optimized voxel-based morphometry for detection of Alzheimer’s disease: aging effect on diagnostic performance. J Nucl Med. 2007;48(12):1961–70.
pubmed: 18006622
doi: 10.2967/jnumed.107.042820
Meltzer CC, Zubieta JK, Brandt J, Tune LE, Mayberg HS, Frost JJ. Regional hypometabolism in Alzheimer’s disease as measured by positron emission tomography after correction for effects of partial volume averaging. Neurology. 1996;47(2):454–61.
pubmed: 8757020
doi: 10.1212/WNL.47.2.454
Brown RK, Bohnen NI, Wong KK, Minoshima S, Frey KA. Brain PET in suspected dementia: patterns of altered FDG metabolism. Radiographics. 2014;34(3):684–701.
pubmed: 24819789
doi: 10.1148/rg.343135065
Minoshima S, Giordani B, Berent S, Frey KA, Foster NL, Kuhl DE. Metabolic reduction in the posterior cingulate cortex in very early Alzheimer’s disease. Ann Neurol. 1997;42(1):85–94.
pubmed: 9225689
doi: 10.1002/ana.410420114
McMurtray AM, Licht E, Yeo T, Krisztal E, Saul RE, Mendez MF. Positron emission tomography facilitates diagnosis of early-onset Alzheimer’s disease. Eur Neurol. 2008;59(1–2):31–7.
pubmed: 17917455
doi: 10.1159/000109258
Langbaum JBS, Chen K, Lee W, Reschke C, Bandy D, Fleisher AS, et al. Categorical and correlational analyses of baseline fluorodeoxyglucose positron emission tomography images from the Alzheimer’s Disease Neuroimaging Initiative (ADNI). NeuroImage. 2009;45(4):1107–16.
pubmed: 19349228
doi: 10.1016/j.neuroimage.2008.12.072
Choo IH, Lee DY, Youn JC, Jhoo JH, Kim KW, Lee DS, et al. Topographic patterns of brain functional impairment progression according to clinical severity staging in 116 Alzheimer disease patients: FDG-PET study. Alz Dis Assoc Dis. 2007;21(2):77–84.
doi: 10.1097/WAD.0b013e3180687418
Diehl J, Grimmer T, Drzezga A, Riemenschneider M, Forstl H, Kurz A. Cerebral metabolic patterns at early stages of frontotemporal dementia and semantic dementia. A PET study. Neurobiol Aging. 2004;25(8):1051–6.
pubmed: 15212830
doi: 10.1016/j.neurobiolaging.2003.10.007
Diehl-Schmid J, Grimmer T, Drzezga A, Bornschein S, Riemenschneider M, Forstl H, et al. Decline of cerebral glucose metabolism in frontotemporal dementia: a longitudinal 18F-FDG-PET-study. Neurobiol Aging. 2007;28(1):42–50.
pubmed: 16448722
doi: 10.1016/j.neurobiolaging.2005.11.002
Foster NL, Heidebrink JL, Clark CM, Jagust WJ, Arnold SE, Barbas NR, et al. FDG-PET improves accuracy in distinguishing frontotemporal dementia and Alzheimer’s disease. Brain. 2007;130:2616–35.
pubmed: 17704526
doi: 10.1093/brain/awm177
Mesulam M. Primary progressive aphasia: a dementia of the language network. Dement Neuropsychol. 2013;7(1):2–9.
pubmed: 24707349
pmcid: 3975615
doi: 10.1590/S1980-57642013DN70100002
Knibb JA, Xuereb JH, Patterson K, Hodges JR. Clinical and pathological characterization of progressive aphasia. Ann Neurol. 2006;59(1):156–65.
pubmed: 16374817
doi: 10.1002/ana.20700
Snowden J, Neary D, Mann D. Frontotemporal lobar degeneration: clinical and pathological relationships. Acta Neuropathol. 2007;114(1):31–8.
pubmed: 17569065
doi: 10.1007/s00401-007-0236-3
Kiymaz T, Khan Suheb MZ, Lui F, De Jesus O. Primary Progressive Aphasia. StatPearls. Treasure Island (FL): StatPearls Publishing Copyright © 2024. StatPearls Publishing LLC.; 2024.
Rascovsky K, Hodges JR, Knopman D, Mendez MF, Kramer JH, Neuhaus J, et al. Sensitivity of revised diagnostic criteria for the behavioural variant of frontotemporal dementia. Brain. 2011;134(Pt 9):2456–77.
pubmed: 21810890
pmcid: 3170532
doi: 10.1093/brain/awr179
McKhann GM, Knopman DS, Chertkow H, Hyman BT, Jack CR Jr., Kawas CH, et al. The diagnosis of dementia due to Alzheimer’s disease: recommendations from the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer’s disease. Alzheimers Dement. 2011;7(3):263–9.
pubmed: 21514250
doi: 10.1016/j.jalz.2011.03.005
Hosaka K, Ishii K, Sakamoto S, Sadato N, Fukuda H, Kato T, et al. Validation of anatomical standardization of FDG PET images of normal brain: comparison of SPM and NEUROSTAT. Eur J Nucl Med Mol I. 2005;32(1):92–7.
doi: 10.1007/s00259-004-1576-z
Saive AL, Royet JP, Plailly J. A review on the neural bases of episodic odor memory: from laboratory-based to autobiographical approaches. Front Behav Neurosci. 2014;8.
Nieuwenhuys R, Voogd J, Van Huijzen C. The human central nervous system: a synopsis and atlas. Springer Science & Business Media; 2007.
Verger A, Doyen M, Campion JY, Guedj E. The pons as reference region for intensity normalization in semi-quantitative analysis of brain (18)FDG PET: application to metabolic changes related to ageing in conventional and digital control databases. EJNMMI Res. 2021;11(1):31.
pubmed: 33761019
pmcid: 7990981
doi: 10.1186/s13550-021-00771-0
Fahmi R, Platsch G. White paper syngo.via Database Comparison in MI neurology workflow. siemens-healthineers.com
Penny WD, Friston KJ, Ashburner JT, Kiebel SJ, Nichols TE. Statistical parametric mapping: the analysis of functional brain images. Elsevier; 2011.
Della Rosa PA, Cerami C, Gallivanone F, Prestia A, Caroli A, Castiglioni I, et al. A standardized [18F]-FDG-PET template for spatial normalization in statistical parametric mapping of dementia. Neuroinformatics. 2014;12(4):575–93.
pubmed: 24952892
doi: 10.1007/s12021-014-9235-4
Radua J, Canales-Rodriguez EJ, Pomarol-Clotet E, Salvador R. Validity of modulation and optimal settings for advanced voxel-based morphometry. NeuroImage. 2014;86:81–90.
pubmed: 23933042
doi: 10.1016/j.neuroimage.2013.07.084
Drake DF, Derado G, Zhang LJ, Bowman FD, Neuroimaging AD. Neuroimaging statistical approaches for determining neural correlates of Alzheimer’s disease via positron emission tomography imaging. Wires Comput Stat. 2023;15(5).
Ashburner J, Barnes G, Chen C-C, Daunizeau J, Flandin G, Friston K, et al. SPM12 manual. Volume 2464. London, UK: Wellcome Trust Centre for Neuroimaging; 2014. 4.
Acton PD, Friston KJ. Statistical parametric mapping in functional neuroimaging: beyond PET and fMRI activation studies. Eur J Nucl Med. 1998;25(7):663–7.
pubmed: 9741993
Stamatakis EA, Glabus MF, Wyper DJ, Barnes A, Wilson JT. Validation of statistical parametric mapping (SPM) in assessing cerebral lesions: a simulation study. NeuroImage. 1999;10(4):397–407.
pubmed: 10493898
doi: 10.1006/nimg.1999.0477
Perani D, Della Rosa PA, Cerami C, Gallivanone F, Fallanca F, Vanoli EG, et al. Validation of an optimized SPM procedure for FDG-PET in dementia diagnosis in a clinical setting. Neuroimage Clin. 2014;6:445–54.
pubmed: 25389519
pmcid: 4225527
doi: 10.1016/j.nicl.2014.10.009
Nestor PJ, Altomare D, Festari C, Drzezga A, Rivolta J, Walker Z, et al. Clinical utility of FDG-PET for the differential diagnosis among the main forms of dementia. Eur J Nucl Med Mol Imaging. 2018;45(9):1509–25.
pubmed: 29736698
doi: 10.1007/s00259-018-4035-y
Gjerum L, Frederiksen KS, Henriksen OM, Law I, Bruun M, Simonsen AH, et al. Evaluating 2-[18F]FDG-PET in differential diagnosis of dementia using a data-driven decision model. NeuroImage: Clin. 2020;27:102267.
pubmed: 32417727
doi: 10.1016/j.nicl.2020.102267
Klein J, Yan XY, Johnson A, Tomljanovic Z, Zou J, Polly K, et al. Olfactory impairment is related to Tau Pathology and Neuroinflammation in Alzheimer’s Disease. J Alzheimers Dis. 2021;80(3):1051–65.
pubmed: 33646153
pmcid: 8044007
doi: 10.3233/JAD-201149
Braak H, Braak E. Neuropathological stageing of Alzheimer-related changes. Acta Neuropathol. 1991;82(4):239–59.
pubmed: 1759558
doi: 10.1007/BF00308809
Therriault J, Pascoal TA, Lussier FZ, Tissot C, Chamoun M, Bezgin G, et al. Biomarker modeling of Alzheimer’s disease using PET-based Braak staging. Nat Aging. 2022;2(6):526–35.
pubmed: 37118445
pmcid: 10154209
doi: 10.1038/s43587-022-00204-0
Fujishiro H, Tsuboi Y, Lin WL, Uchikado H, Dickson DW. Co-localization of tau and alpha-synuclein in the olfactory bulb in Alzheimer’s disease with amygdala Lewy bodies. Acta Neuropathol. 2008;116(1):17–24.
pubmed: 18446351
pmcid: 2719249
doi: 10.1007/s00401-008-0383-1
Compta Y, Revesz T. Neuropathological and biomarker findings in Parkinson’s Disease and Alzheimer’s Disease: from protein aggregates to synaptic dysfunction. J Parkinsons Dis. 2021;11(1):107–21.
pubmed: 33325398
pmcid: 7990431
doi: 10.3233/JPD-202323
Klein A, Andersson J, Ardekani BA, Ashburner J, Avants B, Chiang MC, et al. Evaluation of 14 nonlinear deformation algorithms applied to human brain MRI registration. NeuroImage. 2009;46(3):786–802.
pubmed: 19195496
doi: 10.1016/j.neuroimage.2008.12.037
Martino ME, de Villoria JG, Lacalle-Aurioles M, Olazarán J, Cruz I, Navarro E, et al. Comparison of different methods of spatial normalization of FDG-PET brain images in the voxel-wise analysis of MCI patients and controls. Ann Nucl Med. 2013;27(7):600–9.
pubmed: 23585159
doi: 10.1007/s12149-013-0723-7
Adams DR, Wroblewski KE, Kern DW, Kozloski MJ, Dale W, McClintock MK, et al. Factors Associated with Inaccurate Self-Reporting of olfactory dysfunction in older US adults. Chem Senses. 2017;42(3):223–31.
pubmed: 28007787
Pusswald G, Ocak S, Stögmann E, Lehrner J. Odor identification testing is inferior compared to neurocognitive testing in predicting conversion to Alzheimer’s Disease. Chemosens Percept. 2022;15(2):185–93.
doi: 10.1007/s12078-022-09306-w
Dan X, Wechter N, Gray S, Mohanty JG, Croteau DL, Bohr VA. Olfactory dysfunction in aging and neurodegenerative diseases. Ageing Res Rev. 2021;70:101416.
pubmed: 34325072
pmcid: 8373788
doi: 10.1016/j.arr.2021.101416
Liu S, Jiang Z, Zhao J, Li Z, Li R, Qiu Y, et al. Disparity of smell tests in Alzheimer’s disease and other neurodegenerative disorders: a systematic review and meta-analysis. Front Aging Neurosci. 2023;15:1249512.
pubmed: 37744388
pmcid: 10512741
doi: 10.3389/fnagi.2023.1249512
Mesholam RI, Moberg PJ, Mahr RN, Doty RL. Olfaction in neurodegenerative disease: a meta-analysis of olfactory functioning in Ahlzheimer’s and Parkinson’s diseases. Arch Neurol. 1998;55(1):84–90.
pubmed: 9443714
doi: 10.1001/archneur.55.1.84